No sale: After 3 years of hunting a buyer, bruised Trulance maker Synergy desperate for cashAllbiopro2018-10-27T15:17:26+09:0010월 27th, 2018|
Lundbeck schizophrenia drug fails phase 3, sinking stockAllbiopro2018-10-27T15:15:41+09:0010월 27th, 2018|
Ultragenyx dumps rare nervous system disorder program after phase 3 flopAllbiopro2018-10-27T15:14:50+09:0010월 27th, 2018|
Merck & Co. pumping up to $16bn into biomanufacturingAllbiopro2018-10-27T15:13:58+09:0010월 27th, 2018|
Deal-making digest: IDT’s $80m US contract, WuXi’s strategic partershipAllbiopro2018-10-27T15:13:07+09:0010월 27th, 2018|
Images of antibodies working together against malariaAllbiopro2018-10-27T15:11:19+09:0010월 27th, 2018|
President Trump Will Propose Changes to Lower Medicare Drug PricesAllbiopro2018-10-26T11:02:02+09:0010월 26th, 2018|
The Best Career Advice for New Life Science ProfessionalsAllbiopro2018-10-26T11:01:10+09:0010월 26th, 2018|
Syros Pharma and Genentech: Corporate Culture Enhanced and Defined by Non-Work ActivitiesAllbiopro2018-10-26T11:00:33+09:0010월 26th, 2018|
Regeneron and Roche Duke It out in the Diabetic Retinopathy MarketAllbiopro2018-10-26T10:59:40+09:0010월 26th, 2018|
Biogen, Eisai Breathe Life into BAN2401 with Updated Data Regarding Patients with APOE4 MutationAllbiopro2018-10-26T10:58:49+09:0010월 26th, 2018|
MIT Researchers Discover CRISPR Enzyme That Can Target Almost Half of Genome LocationsAllbiopro2018-10-26T10:57:57+09:0010월 26th, 2018|
Amgen Slashes Price of Repatha by 60% to Make the Drug More AccessibleAllbiopro2018-10-26T10:57:06+09:0010월 26th, 2018|
J&J’s JLABS Incubators Show off Success of First Six YearsAllbiopro2018-10-26T10:56:15+09:0010월 26th, 2018|
